However, pre-transplant MRD-positive NPM1-mutant AML with FLT3-ITD (internal tandem duplication) has significantly poorer outcomes [25] such that FLT3-ITD is classified as intermediate-risk regardless of the presence of NPM1 mutation [30]. The gene discussed is NPM1; the disease is acute myeloid leukemia.